For Physicians. By Physicians.™
For Physicians. By Physicians.™
Ospemifene is an oral medication that is indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Topical estrogen is considered a first line therapy for post-menopausal atrophy. However, there are situations where some women in consultation with their provider may choose not to use local estrogen. According to the FDA, there is insufficient data to use ospemifene in women with breast cancer. While there do not appear to be any cases of ospemifene causing endometrial cancer, a potential risk for this particular malignancy is mentioned in a boxed warning, and surveillance for any signs of endometrial hyperplasia such as irregular uterine bleeding is recommended.
Menopausal Symptoms and Their Management
FDA: Osphena (ospemifene) prescribing information
Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women
Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause
Take a post-test and get CME credits
Please log in to ObGFirst to access the 2T US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
